Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome in a Pivotal, Multicenter, Phase 2 Study (KYSA-8) (LS2.008)

Neurology 2026

View at publisher
Authors: Amanda L. Piquet, Anastasia Zekeridou, Usama Gergis, Jonathan Gutman, Saad S. Kenderian, Mallory Lowe, Sadie Eggmann, Andrew McKeon, Sean Joseph Pittock, Goran Rakočević, Jessica J. Yi, Scott D. Newsome
+10 more Justin Chou, Tom Van Blarcom, Xue Han, John Sun, Shouvonik Sengupta, Ryan Tooker, Aditi Mehta, Dena Grayson, Naji Gehchan, Marinos C. Dalakas
DOI: 10.1212/wnl.0000000000217905
Cited by: 1

Abstract

To evaluate the efficacy and safety of miv-cel (mivocabtagene autoleucel; formerly KYV-101) in patients with stiff person syndrome (SPS) in the pivotal, multicenter, phase 2 study, KYSA-8 (NCT06588491).

Fields of Study & Subjects

CAR-T cell therapy research Autoimmune Neurological Disorders and Treatments Biomedical Ethics and Regulation

Publication details

Journal / source
Neurology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
106
Issue
11_Supplement_1
Publication date
9 June 2026
Language
EN